The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881

被引:4
作者
Feldman, DL [1 ]
Mogelesky, TC [1 ]
Sharif, R [1 ]
Sawyer, WK [1 ]
Jeune, M [1 ]
Hu, CW [1 ]
Leonards, KS [1 ]
Prescott, MF [1 ]
机构
[1] Novartis Inst Biomed Res, Div Pharmaceut, Summit, NJ 07901 USA
关键词
CGP; 2881; probucol; oxidized LDL; antioxidant; hypolipidemic;
D O I
10.1016/S0021-9150(99)00002-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This report describes the in vitro and ex vivo antioxidant properties of a new antioxidant, CGP 2881. This compound is structurally similar to probucol, in that both compounds contain bis-tertiary butyl phenyl groups. However,CGP 2881 consistently inhibited CuSO4 (Cu2+)- and macrophage (MO)-induced oxidation of human low density lipoproteins (LDL) more potently than equimolar concentrations of probucol. CGP 2881 (1 mu mol/l) prolonged the lag phase of diene formation during Cu2+ -induced LDL oxidation by 3.4 versus 1.5-fold prolongation with 1 mu mol/l probucol (P < 0.05 vs CGP 2881). The IC50 for inhibiting the formation of Cu2+-induced thiobarbituric acid-reactive substances (TBARS) was 0.15 mu mol/l for CGP 2881, versus similar to 10 mu mol/l for probucol. The IC50 for MO-induced oxidation of LDL (TBARS) was 0.64 mu mol/l. In contrast, 1 mu mol/l probucol failed to inhibit MO-induced oxidation of LDL. Treatment of cholic acid/cholesterol-fed rats with CGP 2881 (50 mg/kg per day, orally for 5 days) inhibited ex vivo Cu2+-induced oxidation (TBARS) of the very low density lipoproteins (VLDL) + LDL lipoprotein fraction by 93% versus vehicle controls (P < 0.0001), and prolonged the lag phase for Cu2+-induced diene formation by 3.4-fold over vehicle-treated controls. Five days of orally administered CGP 2881 reduced plasma total cholesterol and LDL cholesterol levels to 55 and 54% of vehicle-treated controls, respectively (P < 0.05). In contrast, probucol had no appreciable effect on plasma total cholesterol or LDL cholesterol levels, unless administered for longer than 5 days. Treatment of hypercholesterolemic rabbits with 50 mg/kg per day orally for 5-12 days delayed the lag phase of diene formation during LDL oxidation by 4.3-fold over controls. However, the relative antioxidant potencies of CGP 2881 and probucol seen with oral administration to hypercholesterolemic rabbits were reversed when the compounds were given intravenously. In addition, the effects of these antioxidants were potentiated when given to normocholesterolemic rabbits compared to hypercholesterolemic animals. These data establish that CGP 2881 demonstrates hypolipidemic activity and is a substantially more potent antioxidant than probucol (in vitro and ex vivo). CGP 2881 may be useful as a new antioxidant tool in the effort to better understand the atherogenicity of oxidized LDL (oxLDL). (C) 1999 Published by Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:343 / 355
页数:13
相关论文
共 47 条
[1]  
BARNHART RL, 1989, J LIPID RES, V30, P1703
[2]   VITAMIN-E, CHOLESTEROL, AND LIPIDS DURING ATHEROGENESIS IN RABBITS [J].
BITMAN, J ;
WEYANT, J ;
WOOD, DL ;
WRENN, TR .
LIPIDS, 1976, 11 (06) :449-461
[3]   EFFECT OF DIETARY MONOUNSATURATED AND POLYUNSATURATED FATTY-ACIDS ON THE SUSCEPTIBILITY OF PLASMA LOW-DENSITY LIPOPROTEINS TO OXIDATIVE MODIFICATION [J].
BONANOME, A ;
PAGNAN, A ;
BIFFANTI, S ;
OPPORTUNO, A ;
SORGATO, F ;
DORELLA, M ;
MAIORINO, M ;
URSINI, F .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (04) :529-533
[5]   INCREASED OXIDIZABILITY OF PLASMA LOW-DENSITY-LIPOPROTEIN FROM PATIENTS WITH CORONARY-ARTERY DISEASE [J].
CHIU, HC ;
JENG, JR ;
SHIEH, SM .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1994, 1225 (02) :200-208
[6]  
COMINACINI L, 1994, NUTRITION, V10, P527
[7]   A METHOD FOR THE COMPARATIVE-ASSESSMENT OF ANTIOXIDANTS AS PEROXYL RADICAL SCAVENGERS [J].
DARLEYUSMAR, VM ;
HERSEY, A ;
GARLAND, LG .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (09) :1465-1469
[8]   ENHANCED SUSCEPTIBILITY TO INVITRO OXIDATION OF THE DENSE LOW-DENSITY-LIPOPROTEIN SUBFRACTION IN HEALTHY-SUBJECTS [J].
DEGRAAF, J ;
HAKLEMMERS, HLM ;
HECTORS, MPC ;
DEMACKER, PNM ;
HENDRIKS, JCM ;
STALENHOEF, AFH .
ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (02) :298-306
[9]   EFFECT OF ANTIOXIDANTS ON OXIDATIVE MODIFICATION OF LDL [J].
ESTERBAUER, H ;
PUHL, H ;
DIEBERROTHENEDER, M ;
WAEG, G ;
RABL, H .
ANNALS OF MEDICINE, 1991, 23 (05) :573-581
[10]   THE ROLE OF LIPID-PEROXIDATION AND ANTIOXIDANTS IN OXIDATIVE MODIFICATION OF LDL [J].
ESTERBAUER, H ;
GEBICKI, J ;
PUHL, H ;
JURGENS, G .
FREE RADICAL BIOLOGY AND MEDICINE, 1992, 13 (04) :341-390